A previous study aimed to assess the effect of omalizumab, an anti-IgE mAb, reported histological and clinical improvement in only 33% of patients [77], consistent with the concept that EoE is not an IgE-mediated disease; otherwise, it is associated with IgG4 [78]. The gene discussed is IGHE; the disease is glycogen storage disease VI.